UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the Month of March 2026 (Report No. 5)

 

Commission File Number: 001-40753

 

ICECURE MEDICAL Ltd.

(Translation of registrant’s name into English)

 

7 Ha’Eshel St., PO Box 3163

Caesarea, 3079504 Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

 

 Form 20-F       Form 40-F

 

 

 

 

CONTENTS

 

On March 17, 2026, IceCure Medical Ltd. (the “Company”) announced that Mr. Li Haixiang resigned as a member of the Board of Directors, effective March 17, 2026. Mr. Haixiang’s resignation was not related to any disagreement with the Company on any matter relating to its operations, policies or practices.

 

This Report of Foreign Private Issuer on Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File Nos. 333-290046333-267272 and 333-258660) and Form S-8 (File Nos. 333-270982333-264578333-262620 and 333-281587), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this Report of Foreign Private Issuer on Form 6-K is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

 

1

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  IceCure Medical Ltd.
     
Date: March 17, 2026 By: /s/ Eyal Shamir
    Eyal Shamir
    Chief Executive Officer

 

2